Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Community Acquired Pneumonia - Overview
Community Acquired Pneumonia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Community Acquired Pneumonia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Community Acquired Pneumonia - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
Beijing Fogangren Bio-Pharm Tech Co Ltd
BioAegis Therapeutics Inc
Biotest AG
Combioxin SA
InflaRx NV
ioGenetics Inc
Iterum Therapeutics Plc
Kyorin Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Merck & Co Inc
briva Therapeutics Plc
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Tetraphase Pharmaceuticals Inc
Wockhardt Ltd
Community Acquired Pneumonia - Drug Profiles
BT-086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAL-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftobiprole medocaril - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cx-611 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBAF-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lascufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemonoxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxytetracycline hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Community Acquired Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulopenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulopenem etzadroxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tebipenem pivoxil hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Community Acquired Pneumonia - Dormant Projects
Community Acquired Pneumonia - Discontinued Products
Community Acquired Pneumonia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Community Acquired Pneumonia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Community Acquired Pneumonia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Community Acquired Pneumonia - Pipeline by Basilea Pharmaceutica Ltd, H2 2019
Community Acquired Pneumonia - Pipeline by Beijing Fogangren Bio-Pharm Tech Co Ltd, H2 2019
Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics Inc, H2 2019
Community Acquired Pneumonia - Pipeline by Biotest AG, H2 2019
Community Acquired Pneumonia - Pipeline by Combioxin SA, H2 2019
Community Acquired Pneumonia - Pipeline by InflaRx NV, H2 2019
Community Acquired Pneumonia - Pipeline by ioGenetics Inc, H2 2019
Community Acquired Pneumonia - Pipeline by Iterum Therapeutics Plc, H2 2019
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Community Acquired Pneumonia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
Community Acquired Pneumonia - Pipeline by Merck & Co Inc, H2 2019
Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics Plc, H2 2019
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, H2 2019
Community Acquired Pneumonia - Pipeline by ProThera Biologics Inc, H2 2019
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2019
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2019
Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, H2 2019
Community Acquired Pneumonia - Dormant Projects, H2 2019
Community Acquired Pneumonia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Community Acquired Pneumonia - Discontinued Products, H2 2019